PCRX · Company research
Pacira BioSciences, Inc. Common Stock (PCRX): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
26records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Pacira BioSciences, Inc. - Common Stock (Nasdaq:PCRX) Stock Quote - FinancialContent | Pacira BioSciences, Inc. - Common Stock (Nasdaq:PCRX) Stock Quote FinancialContent | View source ↗ | FinancialContent | Oct 16, 2026 | neutral | 0 | 0.6 |
| Pacira BioSciences, Inc. (PCRX) Stock forecasts - Yahoo Finance UK | Pacira BioSciences, Inc. (PCRX) Stock forecasts Yahoo Finance UK | View source ↗ | Yahoo Finance UK | Oct 15, 2026 | neutral | 0 | 0.6 |
| Pacira BioSciences, Inc. (PCRX) Stock Forecasts - Yahoo! Finance Canada | Pacira BioSciences, Inc. (PCRX) Stock Forecasts Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 15, 2026 | neutral | 0 | 0.6 |
| Pacira BioSciences, Inc. (PCRX) Stock Forecasts - Yahoo Finance | Pacira BioSciences, Inc. (PCRX) Stock Forecasts Yahoo Finance | View source ↗ | Yahoo Finance | Oct 15, 2026 | neutral | 0 | 0.6 |
| Seven investors report stakes below 5% in Pacira BioSciences (PCRX). - Stock Titan | Seven investors report stakes below 5% in Pacira BioSciences (PCRX). Stock Titan | View source ↗ | Stock Titan | Oct 13, 2026 | neutral | 0 | 0.6 |
| Pacira BioSciences, Inc. (PCRX) Stock Forecasts - Yahoo! Finance Canada | Pacira BioSciences, Inc. (PCRX) Stock Forecasts Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 10, 2026 | neutral | 0 | 0.6 |
| Pacira BioSciences, Inc. (PCRX) Stock Price, News, Quote & History - Yahoo! Finance Canada | Pacira BioSciences, Inc. (PCRX) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 10, 2026 | neutral | 0 | 0.6 |
| After exercising options, Lauren Riker sells 6,000 Pacira BioSciences (PCRX) shares. - Stock Titan | After exercising options, Lauren Riker sells 6,000 Pacira BioSciences (PCRX) shares. Stock Titan | View source ↗ | Stock Titan | Oct 9, 2026 | neutral | 0 | 0.6 |
| Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio | Viatris (VTRS) has agreed to acquire Pacira BioSciences (PCRX) for $1.65 billion in cash at $36.50 per share, expected to close by end of 2026. The acquisition adds two marketed pain therapies (Exparel and Zilretta) generating $350.5 million in H1 2026 sales, plus a mid-stage gene therapy candidate (PCRX-201) for knee osteoarthritis. The deal is expected to be immediately accretive to Viatris' financial metrics and strengthen its non-opioid pain management portfolio. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 1 | 1 |
| Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio | Viatris (VTRS) has agreed to acquire Pacira BioSciences (PCRX) for $1.65 billion in cash at $36.50 per share, expected to close by end of 2026. The acquisition adds two marketed pain therapies (Exparel and Zilretta) generating $350.5 million in H1 2026 sales, plus a mid-stage gene therapy candidate (PCRX-201) for knee osteoarthritis. The deal is expected to be immediately accretive to Viatris' financial metrics and strengthen its non-opioid pain management portfolio. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 1 | 1 |
| Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio - TradingView | Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio TradingView | View source ↗ | TradingView | Oct 9, 2026 | neutral | 0 | 0.6 |
| Viatris to Acquire Pacira BioSciences (PCRX) at $36.50 per Share, Stock Surges 44% - GuruFocus | Viatris to Acquire Pacira BioSciences (PCRX) at $36.50 per Share, Stock Surges 44% GuruFocus | View source ↗ | GuruFocus | Oct 8, 2026 | neutral | 0 | 0.6 |
| Pacira BioSciences jumps 44% on Viatris acquisition deal (PCRX:NASDAQ) - Seeking Alpha | Pacira BioSciences jumps 44% on Viatris acquisition deal (PCRX:NASDAQ) Seeking Alpha | View source ↗ | Seeking Alpha | Oct 8, 2026 | neutral | 0 | 0.6 |
| HAE, PCRX Stocks Hit Multi-Year Highs Amid Broader Market Selloff – What’s Driving The Momentum Today? - TradingView | HAE, PCRX Stocks Hit Multi-Year Highs Amid Broader Market Selloff – What’s Driving The Momentum Today? TradingView | View source ↗ | TradingView | Oct 8, 2026 | neutral | 0 | 0.6 |
| Why Pacira BioSciences Skyrocketed Today | Pacira BioSciences surged 44% after announcing its acquisition by Viatris for $36.50 per share, valuing the company at approximately $1.65 billion. The deal represents a 45% premium to the previous closing price and is expected to close by end of 2026. Viatris plans to leverage Pacira's non-opioid pain management products, including Exparel and Zilretta, to strengthen its innovative medicines business. | View source ↗ | The Motley Fool | Oct 8, 2026 | bullish | 0.5 | 1 |
| Why Pacira BioSciences Skyrocketed Today | Pacira BioSciences surged 44% after announcing its acquisition by Viatris for $36.50 per share, valuing the company at approximately $1.65 billion. The deal represents a 45% premium to the previous closing price and is expected to close by end of 2026. Viatris plans to leverage Pacira's non-opioid pain management products, including Exparel and Zilretta, to strengthen its innovative medicines business. | View source ↗ | The Motley Fool | Oct 8, 2026 | bullish | 0.5 | 1 |
| Why Pacira BioSciences Skyrocketed Today | Pacira BioSciences surged 44% after announcing its acquisition by Viatris for $36.50 per share, valuing the company at approximately $1.65 billion. The deal represents a 45% premium to the previous closing price and is expected to close by end of 2026. Viatris plans to leverage Pacira's non-opioid pain management products, including Exparel and Zilretta, to strengthen its innovative medicines business. | View source ↗ | The Motley Fool | Oct 8, 2026 | bullish | 0.5 | 1 |
| Traders are paying attention to the gapping stocks in Thursday's session. - ChartMill | Traders are paying attention to the gapping stocks in Thursday's session. ChartMill | View source ↗ | ChartMill | Oct 8, 2026 | neutral | 0 | 0.6 |
| A 6,000-share sale is proposed by Lauren B. Riker of Pacira BioSciences (PCRX). - Stock Titan | A 6,000-share sale is proposed by Lauren B. Riker of Pacira BioSciences (PCRX). Stock Titan | View source ↗ | Stock Titan | Oct 8, 2026 | neutral | 0 | 0.6 |
| A $1.65 billion deal would put two non-opioid pain medicines under Viatris. - Stock Titan | A $1.65 billion deal would put two non-opioid pain medicines under Viatris. Stock Titan | View source ↗ | Stock Titan | Oct 8, 2026 | neutral | 0 | 0.6 |
| 2 Stocks Drawing Bearish Options Activity Today - Schaeffer's Investment Research | 2 Stocks Drawing Bearish Options Activity Today Schaeffer's Investment Research | View source ↗ | Schaeffer's Investment Research | Oct 8, 2026 | neutral | 0 | 0.6 |
| 76% of surveyed caregivers worried about the first days of home recovery - Stock Titan | 76% of surveyed caregivers worried about the first days of home recovery Stock Titan | View source ↗ | Stock Titan | Oct 7, 2026 | neutral | 0 | 0.6 |
| PCRX Expands Exparel Commercial Reach in Europe Through Molteni Deal | Pacira BioSciences announced an exclusive agreement with Italian pharmaceutical company Molteni Farmaceutici to distribute and commercialize Exparel across the EU and UK. Molteni will launch the long-acting local anesthetic in Italy, Germany, Austria, and Poland starting in 2027, while Pacira retains manufacturing rights and will receive upfront payments, supply fees, and royalties. The deal supports Pacira's international expansion strategy while the company advances other pain management products including Zilretta and PCRX-201. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | bullish | 0.25 | 1 |
| PCRX Expands Exparel Commercial Reach in Europe Through Molteni Deal | Pacira BioSciences announced an exclusive agreement with Italian pharmaceutical company Molteni Farmaceutici to distribute and commercialize Exparel across the EU and UK. Molteni will launch the long-acting local anesthetic in Italy, Germany, Austria, and Poland starting in 2027, while Pacira retains manufacturing rights and will receive upfront payments, supply fees, and royalties. The deal supports Pacira's international expansion strategy while the company advances other pain management products including Zilretta and PCRX-201. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | bullish | 0.25 | 1 |
| A postsurgery pain medicine is planned to launch in four countries; first sales are expected in 2027. - Stock Titan | A postsurgery pain medicine is planned to launch in four countries; first sales are expected in 2027. Stock Titan | View source ↗ | Stock Titan | Oct 5, 2026 | neutral | 0 | 0.6 |
| Pacira BioSciences (PCRX) Stock Looks Expensive Relative To Its Earnings Power - Simply Wall Street | Pacira BioSciences (PCRX) Stock Looks Expensive Relative To Its Earnings Power Simply Wall Street | View source ↗ | Simply Wall Street | Sep 29, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.